image

Drug Discovery Informatics Market Report Scope & Overview:

The Drug Discovery Informatics Market Size was surveyed at USD 3.56 billion out of 2023 and is supposed to addition to USD 8.52 billion by 2031, stretching out at a CAGR of 11.5% from 2024 to 2031.

A technology approach for evaluating and deciphering massive amounts of biological data is called drug discovery informatics. The information is gathered from clinical laboratory research experiments and is used to produce insights into the creation of various medications. Drug discovery informatics uses complex bioinformatics algorithms to process information about drugs, diseases, proteins, pathways, gene expression, and sequence data. It also extends the flexible architecture to build new, specialised approaches and algorithms for various aspects of drug discovery, which would help to lower the cost of drug development. Numerous hardware- and software-based tools are used for sequencing, target data processing, data visualization, docking, molecular modelling, and database security in the process of finding and developing new drugs. Because of this, it is commonly utilised by healthcare facilities, businesses involved in the pharmaceutical and biotechnology industries, and contract research organisations (CROs).

Drug Discovery Informatics Market Revenue Analysis

Get more information on Drug Discovery Informatics Market - Request Sample Report

MARKET DYNAMICS

DRIVERS

  • Increased investment in informatics research by the biotechnology and pharmaceutical sectors

  • Growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases

  • Utilize informatics to concentrate on drug discovery

RESTRAINTS

  • Informatics software setup fees are very expensive

OPPORTUNITIES

  • Expired patents

  • expanding market for biologics and the biotechnology sector

  • expansion in emerging markets

CHALLENGES

  • Lack of qualified professionals

IMPACT OF COVID-19

Countries' health systems have made significant investments in R&D to fight the COVID-19 virus during the current pandemic. Finding small molecule medications for COVID-19 treatment has been a focus of research teams around the world. The need for the drug discovery bioinformatics market therefore increases as a result of the ongoing pandemic and the increased drug development of medications. According to a study published in the journal Chemical Society Review with the title "A critical overview of computational approaches employed for COVID-19 drug discovery," a significant portion of research has been devoted to the identification of new drug candidates or the repurposing of already approved medications for COVID-19. According to the researcher, in order to find new drugs and drug combinations, computational tools must produce testable, experimentally actionable hypotheses. He also contends that open science and quick dissemination of research findings are essential for accelerating the development of novel, urgently needed COVID-19 therapeutics. As a result, the COVID-19 has a big impact on the market for drug discovery information.

MARKET ESTIMATION

By Workflow Type

Drug Discovery and Drug Development are two segments of the market. A substantial focus on the creation of precision pharmaceuticals caused the discovery informatics to dominate the industry. Personalized medical care is provided to patients based on their genetic and molecular profiles. Businesses offer discovery informatics solutions for utilising analytics for quick drug discovery, such PerkinElmer, Inc. The use of bioinformatics for quick medicine discovery is also being supported by the governments of numerous developing nations.

By Mode Type

Due to an increase in collaborations between pharmaceutical companies and contract development and manufacturing businesses, the category will continue to grow at a consistent CAGR during the projection period (CDMOs). Reports on novel drug entities are created by contract research organisations (CROs), which are then used by the sponsor or drug maker to submit to the U.S. FDA.

Partnering with a CRO that offers the same informatics solution as a pharmaceutical or biotechnology company has advantages. The CRO and the companies use a shared informatics platform to track study progress in a manner similar to how they track their own internal research. This aids the business in reducing costs and increasing productivity, which is anticipated to present the market's firms with a wealth of lucrative prospects.

By Service Type

With the fastest CAGR during the forecast period, the category will continue to hold the leading position. The creation of primary and secondary databases of nucleic acid, protein, and other biomolecule sequences makes extensive use of bioinformatic tools. The mining and storage of genome sequencing data are done using informatics tools in order to discover the genes and targeted proteins that will aid in the creation of prospective medications. Additionally, using various databases and sequence analysis tools like CLUSTALW, BLAST, and FASTA are necessary for doing fundamental drug discovery research. The introduction of novel and cutting-edge software is also a factor in the segment's expansion.

Users of the informatics platform can organize peptide sequences according to colour code and property. Due to its extensive use in the drug development process, molecular modelling is becoming more and more popular. These technologies are used to model and simulate biological systems and tiny molecules in order to comprehend and predict their molecular behavior. Additionally, they improve hit-to-lead optimization and hit discovery's cost-efficiency more quickly.

KEY MARKET SEGMENTS:

By Workflow Type

  • Discovery Informatics

  • Identification, Validation, & Assay Development Informatics

  • Lead Generation

  • Development Informatics

  • Lead Optimization

  • FHD Preparation

  • Phase IA

  • Phase IB/2

By Mode Type

  • Outsourced

  • In-house

By Service Type

REGIONAL ANALYSIS

There are four primary geographic divisions for the medication revelation informatics market: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market for drug discovery informatics was dominated by North America, with Europe a close second. The presence of established CROs and increased R&D spending by pharmaceutical and biopharmaceutical businesses are two factors that contribute to North America's significant market share globally.

During the projected period, the CAGR for the Asia Pacific region is predicted to be the highest. Factors include the booming pharmaceutical and biopharmaceutical industries, the rise in CROs, and the lack of strict standards for drug discovery processes are all contributing factors.

Drug Discovery Informatics Market By Region

Need any customization research on Drug Discovery Informatics Market - Enquiry Now

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

KEY PLAYERS:

Some of the major key players are as follows: Accenture, Boehringer Ingelheim International GmbH, Oracle, Certara, Agilent Technologies, Inc., Charles River, Infosys Ltd., Eurofins DiscoverX Products, Laboratories, Jubilant Biosys, Collaborative Drug Discovery, Inc., Selvita and Other Players.

Oracle-Company Financial Analysis

Company Landscape Analysis

Drug Discovery Informatics Market Report Scope:
Report Attributes Details
Market Size in 2023  US$ 3.56 Billion
Market Size by 2031  US$ 8.52 Billion
CAGR  CAGR of 11.5% From 2024 to 2031
Base Year  2023
Forecast Period  2024-2031
Historical Data  2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Workflow Type (Discovery Informatics (Identification, Validation, & Assay Development Informatics, Lead Generation), Development Informatics (Lead Optimization, FHD Preparation, Phase IA, Phase IB/2)
• By Mode Type (Outsourced, In-house)
• By Service Type (Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Accenture, Boehringer Ingelheim International GmbH, Oracle, Certara, Agilent Technologies, Inc., Charles River, Infosys Ltd., Eurofins DiscoverX Products, Laboratories, Jubilant Biosys, Collaborative Drug Discovery, Inc., Selvita
DRIVERS • Increased investment in informatics research by the biotechnology and pharmaceutical sectors
• Growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases
• Utilize informatics to concentrate on drug discovery
RESTRAINTS • Informatics software setup fees are very expensive

Frequently Asked Questions

Ans: The Drug Discovery Informatics market size was valued at US$ 3.56 billion in 2023.

Ans: The Drug Discovery Informatics Market is to grow at a CAGR of 11.5% over the forecast period 2024-2031.

Outsourced, and In-house are the sub segments of component of Drug Discovery Informatics market.

Drivers, Restraints, Opportunities, and Challenges are the factors of marketing dynamics Drug Discovery Informatics market.

The growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases utilize informatics to concentrate on drug discovery are the key drivers of the Drug Discovery Informatics market.

Table of Contents

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies

4.3.2.1 US

4.3.2.2 Canada

4.3.2.3 Germany

4.3.2.4 France

4.3.2.5 United Kingdom

4.3.2.6 China

4.3.2.7 Japan

4.3.2.8 South Korea

4.3.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7.  PEST Analysis

  

8. Drug Discovery Informatics Market Segmentation, By Workflow Type

8.1 Discovery Informatics

8.1.1 Identification, Validation, & Assay Development Informatics

8.1.2 Lead Generation

8.2 Development Informatics

8.2.1 Lead Optimization

8.2.2 FHD Preparation

8.2.3 Phase IA

8.2.4 Phase IB/2

9. Drug Discovery Informatics Market Segmentation, By Mode Type

9.1 Outsourced

9.2 In-house

10. Drug Discovery Informatics Market Segmentation, By Service Type

10.1 Sequence Analysis Platforms

10.2 Molecular Modeling

10.3 Docking

10.4 Clinical Trial Data Management

11. Regional Analysis

11.1 Introduction

11.2 North America

11.2.1 USA

11.2.2 Canada

11.2.3 Mexico

11.3 Europe

11.3.1 Germany

11.3.2 UK

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 The Netherlands

11.3.7 Rest of Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 South Korea

11.4.3 China

11.4.4 India

11.4.5 Australia

11.4.6 Rest of Asia-Pacific

11.5 The Middle East & Africa

11.5.1 Israel

11.5.2 UAE

11.5.3 South Africa

11.5.4 Rest

11.6 Latin America

11.6.1 Brazil

11.6.2 Argentina

11.6.3 Rest of Latin America

12.Company Profiles

12.1 Accenture

12.1.1 Financial

12.1.2 Products/ Services Offered

12.1.3 SWOT Analysis

12.1.4 The SNS view

12.2 Boehringer Ingelheim International GmbH

12.3 Oracle

12.4 Certara

12.5 Agilent Technologies, Inc.

12.6 Charles River

12.7 Infosys Ltd.

12.7 Eurofins DiscoverX Products

12.8 Laboratories

12.9 Jubilant Biosys

12.10 Collaborative Drug Discovery, Inc.

13. Competitive Landscape

13.1 Competitive Benchmark

13.2 Market Share Analysis

13.3 Recent Developments

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone